FDA Approves First mRNA Flu Vaccine for Older Adults

The U.S. Food and Drug Administration (FDA) has officially approved the first influenza vaccine that uses mRNA technology. The new vaccine, called mFLUSIVA, is designed for adults aged 50 and older. This development is significant because it brings the same technology used to create COVID-19 vaccines into the fight against the seasonal flu. According to Moderna, the company that created the vaccine, mFLUSIVA will be available for the upcoming 2026-2027 respiratory virus season.

For many years, traditional flu vaccines have been made using older methods. However, mRNA technology works differently by teaching the body how to recognize and fight viruses. Stéphane Bancel, the CEO of Moderna, stated that the FDA’s decision shows the "continued strength and versatility" of their mRNA platform. He added that the vaccine provides an important new option for older adults, who are often at higher risk of serious illness from the flu.

The path to approval was not simple. Earlier this year, the FDA initially refused to review Moderna’s application. According to NPR, the agency had concerns about the study methods and whether the vaccine was being compared correctly to the best existing options. However, after facing pressure from public health experts and the pharmaceutical industry, the agency reconsidered. In June, an independent group of outside advisers met to review the data and voted unanimously to recommend the vaccine for approval.

Research supporting the vaccine included a large study with more than 40,000 participants. Results showed that mFLUSIVA was safe and appeared to provide stronger protection than traditional flu shots. For adults aged 65 and older, the vaccine showed a relative effectiveness of 27.4% compared to standard shots. Most side effects reported by participants were mild or moderate and did not last long.

The approval comes during a time of debate regarding vaccine technology. The current administration, led by Health and Human Services Secretary Robert F. Kennedy Jr., has been known for being critical of vaccines and mRNA technology. NPR reports that the administration had previously cut funding for mRNA research and limited access to COVID-19 vaccines. Despite this, the FDA moved forward with the approval after Moderna provided more data and agreed to conduct further studies on the vaccine’s effectiveness after it hits the market.

Not everyone is happy with the decision. Some critics, such as Dr. Brian Hooker from the group Children's Health Defense, argue that the technology is still too new and needs more study. However, many in the medical community see this as a major step forward. Dr. Jeanne Marrazzo, chief executive officer of the Infectious Diseases Society of America, noted that the FDA is showing it is open to this platform. She explained that this could help the country respond better not only to bad flu seasons but also to other future biological threats.

One of the biggest advantages of mRNA technology is how quickly it can be updated. Standard vaccines can take a long time to manufacture, but mRNA vaccines can be produced much faster. This is important because flu viruses can change unexpectedly from year to year. Ronald Nahass, president of the Infectious Diseases Society of America, said that this ability to respond quickly to new virus mutations is a major benefit. He believes that proving the success of mRNA for the flu opens the door to creating targeted vaccines for many other diseases in the future.

As the 2026-2027 flu season approaches, public health officials are watching closely to see how the new vaccine performs. While the debate over mRNA technology continues in political circles, the scientific community remains focused on the potential for better health outcomes. For now, mFLUSIVA represents a new tool for doctors to protect older patients against a virus that remains a significant public health challenge every year.